Diabetes Drugs May Ease Hidradenitis Suppurativa and Heart Risk, Study Suggests
A Mount Sinai retrospective analysis suggests GLP-1 receptor agonists may reduce cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa.
A Mount Sinai retrospective analysis suggests GLP-1 receptor agonists may reduce cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa.
A JAMA cross-sectional study quantifies how frequently commercially insured women in the United States begin GLP-1 receptor agonist prescriptions after ...
A new bibliometric analysis of 3,736 articles maps how GLP-1-based diabetes research exploded from 7 papers in 2004 to 589 ...
UTHealth Houston researchers have received a five-year, $4 million NIH grant to identify genetic markers and molecular mechanisms behind weight ...
A network meta-analysis of 29 randomized trials finds semaglutide best targets antipsychotic-related weight and blood sugar problems while metformin shows ...
A new perspective in Advances in Therapy argues that lean mass loss during incretin therapy reflects physiological body composition remodeling ...
A network meta-analysis of 43 studies and over 930,000 patients finds bariatric surgery reduces major cardiovascular events, heart failure and ...
A post hoc analysis of the SCHOLAR study found that over 42 percent of Chinese adults starting semaglutide also took ...
A new review in Diabetes Therapy finds that three amylin-based agonists—zenagamtide, eloralintide and CagriSema—deliver unprecedented weight loss and, in some ...
A new online study shows that asking GLP-1RA users to photograph their medications is feasible and reveals that most compounded ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine